PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-21.42%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-28.98%
Negative gross profit growth while VET is at 39.33%. Joel Greenblatt would examine cost competitiveness or demand decline.
-57.88%
Negative EBIT growth while VET is at 77.35%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-57.88%
Negative operating income growth while VET is at 77.35%. Joel Greenblatt would press for urgent turnaround measures.
50.49%
Positive net income growth while VET is negative. John Neff might see a big relative performance advantage.
50.61%
Positive EPS growth while VET is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
50.48%
Positive diluted EPS growth while VET is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.27%
Share reduction more than 1.5x VET's 1.64%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
No Data
No Data available this quarter, please select a different quarter.
2.35%
Maintaining or increasing dividends while VET cut them. John Neff might see a strong edge in shareholder returns.
-1.10%
Negative OCF growth while VET is at 34.88%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
940.00%
FCF growth above 1.5x VET's 342.78%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-63.78%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-37.08%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-43.90%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-84.61%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-57.43%
Negative 5Y OCF/share CAGR while VET is at 3.81%. Joel Greenblatt would question the firm’s operational model or cost structure.
-45.43%
Negative 3Y OCF/share CAGR while VET stands at 47.08%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-130.43%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-1172.56%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-568.09%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-54.65%
Negative equity/share CAGR over 10 years while VET stands at 130.23%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-68.92%
Negative 5Y equity/share growth while VET is at 14.45%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
1.71%
Below 50% of VET's 16.77%. Michael Burry suspects a serious short-term disadvantage in building book value.
-28.47%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
-76.83%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-76.83%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
37.45%
AR growth well above VET's 1.34%. Michael Burry fears inflated revenue or higher default risk in the near future.
-26.47%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-9.54%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.46%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-10.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-7.63%
We cut SG&A while VET invests at 7.72%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.